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ABSTRACT 
Bone morphogenetic proteins (BMPs) are growth and differentiation factors involved 
during development in morphogenesis, organogenesis and later mainly in regeneration 
processes, in particular in bone where they are responsible for osteoinduction. For more 
than a decade, recombinant human (rh)BMP-2 has been used in the clinic for lumbar 
spinal fusion at non-physiological high dosages that appear to be causative for side 
effects, like male sterility. A possible strategy to reduce the effective amount of rhBMP-2 
in the clinic is the co-delivery with an enhancer of BMPs’ activity. In an earlier study, we 
showed that N-methylpyrrolidone (NMP) enhances BMP activity in vitro and in vivo. Here 
we report on the development of a slow and sustained double delivery of rhBMP-2 and 
NMP via an in situ forming implant based on poly(lactide-co-glycolide). The results 
showed that the release of NMP can be adjusted by varying the lactide/glycolide ratio 
and the polymer’s molecular weight. The same applied to rhBMP-2, with release rates 
that could be sustained from two to three weeks. In the in vivo model of a critical size 
defect in the calvarial bone of rabbits, the implant containing 50 mol% lactide performed 
better than the one having 75 mol% lactide in terms of defect bridging and extent of 
bony regenerated area. In situ forming implants for the double delivery of the BMP 
enhancer NMP and rhBMP-2 appear to be promising delivery systems in bone 
regeneration.   
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1. Introduction 
Bone morphogenetic proteins (BMPs), members of the transforming growth 
factor-β superfamily of proteins, play an extremely important role in bone development 
and regeneration.  The BMP-2 growth factor has been shown to maintain the 
osteoprogenitor cells, promote differentiation of osteoblasts, and is critical in bone 
healing [1]. Because of its major role in these processes, there have been significant 
efforts to deliver BMPs in an efficient manner to regenerate bone and commercial, FDA 
approved rhBMP products are available, e.g. OP-1™ (BMP-7, Olympus, Stryker) or 
BMP-2 (Infuse Bone Graft, Medtronic, Minneapolis). Numerous studies have explored 
synthetic polymers, naturally-derived materials, and calcium phosphates in formats 
including gels, injectable liquids, scaffolds, and particles [2-6]. Despite this body of work, 
high concentrations of rhBMPs are still needed for effective therapies. Doses on the 
order of milligrams are delivered to the patient, while physiologic concentrations are 
several orders of magnitude lower [7]. Various side effects, including ectopic bone 
formation, urogenital events, male sterility, osteolysis, and neck and throat swelling, can 
be caused or exacerbated by these high concentrations [8]. Additionally, since BMPs are 
produced recombinantly, they are very expensive treatments, especially when large 
doses are required.  
Previously, our laboratory discovered the enhancing effects of N-methyl 
pyrrolidone (NMP) on rhBMP-2, which offers a means to lower the efficacious delivered 
BMP dose [9]. NMP has been demonstrated to both increase bone forming activities of 
osteoblasts and decrease bone resorption of osteoclasts [10]. An in vivo study using a 
rabbit calvarial defect model showed significantly higher bone regeneration with NMP 
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alone by increasing the activity of the natural locally deposited autologous BMP [9]. 
Furthermore, NMP is used as an injectable pharmaceutical excipient in FDA approved 
formulations and regarded as safe up to certain concentrations [11, 12]. Moreover, NMP 
is inexpensive and easily attainable; it is commonly used in various industries as a 
plasticizer and solvent. 
To be able to take full advantage of the bone augmenting properties of NMP, it is 
important to retain NMP and deliver it over a sustained period of time. Previous studies 
have demonstrated the importance of slow delivery of rhBMP to obtain the best possible 
bone regeneration and provide the safest therapy [2, 13]. However, NMP, which is a 
small water and organic miscible molecule, is not easy to deliver slowly; NMP is cleared 
from the body within a few hours [14, 15]. Typically, conventional drug delivery 
strategies are not adapted to this type of molecule.  
One drug delivery system that was developed to deliver a variety of different 
compounds utilizes NMP or another organic solvent to dissolve polyesters along with the 
drug substance. Upon immersion in an aqueous solution, a phase separation occurs in 
this so-called in situ forming implant (ISFI), and the water insoluble polymer precipitates 
to form a membrane surrounding a liquid interior [16]. Through diffusion of water into the 
ISFI and the efflux of the organic solvent, the drug is released over a sustained period of 
time with the release profile dependent on multiple factors, including the solvent, 
polymer properties, and composition. Four products based on Atrigel®, an ISFI system 
developed by Atrix Laboratories, were FDA approved. These four products are (1) 
Atrisorb® without any drug for periodontal regeneration, (2) Atridox® with doxycycline for 
subgingival delivery for periodontal treatment, (3) Doxyrobe® with doxycycline for animal 
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periodontal treatment, and (4) Eligard™ with leuprolide acetate for prostate cancer 
therapy [17]. Several of the clinical applications of ISFIs target bone, with Atridox® and 
Atrisorb® for alveolar ridge augmentation and other periodontal bone defects [17-19], 
and an ISFI combined with tricalcium phosphate for non-weight bearing orthopedic 
applications [20].The ISFI system possesses many benefits, including injectability, fast 
application, space filling without the need to cut material to size, and biocompatibility. 
Furthermore it was shown to be bioadhesive to bone and teeth and to facilitate local 
delivery and limited pain [18, 21].  
Instead of using the ISFI system to deliver a classical drug, we have explored this 
technology to extend the release of NMP, which itself is a bioactive substance [9, 10]. By 
examining the dependence of the release profile on polymer properties, we have 
prolonged the release of NMP from hours to a few weeks. Moreover, this system has 
been expanded to also include BMP-2 for a greater enhancement of bone regeneration, 
rather than relying solely on the amount of growth factor that is naturally present. A 
calvarial defect model study in rabbits was performed to demonstrate the efficacy of this 
double delivery system.  
 
2. Materials and Methods 
 All animal procedures were approved by the local authorities (Kantonales 
Veterinäramt, Zürich, Switzerland, approval 107/2012) and are in line with the European 
Committee Council Directive Ref. 86/609/EEC. 
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2.1 Implant Formation 
Poly(DL-lactide) (PLA) and poly(DL-lactide-co-glycolide) PLGA were obtained 
from Boehringer Ingelheim (Ingelheim am Rhein, Germany). Polymers were dissolved 
overnight-shaking at 37°C to final 40 wt% in pure NMP (Sigma-Aldrich, St. Louis, MO) or 
a combination of NMP with water. Table 1 lists the polymers, with the weight average 
molecular weight and polydispersity as measured with gel permeation chromatography 
(see below for methods) and percentage lactide and glycolide  
Table 1: List of polymers used in the ISFIs 
Polymer Name Weight 
average 
molecular 
weight (Mw) 
[kDa] 
Polydispersity 
index 
Lactide [mol%] Glycolide 
[mol%] 
RG502 14.5 2.06 50 50 
RG503  42.6 2.25 50 50 
RG752  12.2 1.99 75 25 
R202  9.7 2.04 100 0 
 
2.2 NMP Release  
Release studies were performed by injecting 500 mg of the dissolved polymer 
into a cylindrical stainless steel mesh basket (10 mm diameter; 13 mm height; 0.6 mm 
mesh size) and immediately immersing it into 300 mL of phosphate buffered saline 
(PBS), 137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 KH2PO4, pH 7.4. With the 
mesh suspended in the middle of the liquid, samples were maintained at 37°C and 
shaking at 100 rpm. At predefined time points (30 minutes, 1, 2, 4, 6, 8, and 24 hours, 2, 
3, 7, 10, 14, 21, and 28 days), a 1-mL aliquot of release buffer was removed and saved 
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for later analysis. NMP concentration was analyzed using liquid chromatography-mass 
spectrometry on a Thermo Scientific LTQ XL instrument (Thermo Fisher Scientific, 
Waltham, MA) with a Hypersil Gold column (100 x 1 mm dimensions, 1.9 µm particle 
size, Thermo Fisher Scientific).  A gradient of water and methanol, each with 0.1% 
formic acid was used to analyse the samples, producing a UV peak that corresponded to 
the molecular weight of NMP. NMP concentration was quantified using the area under 
the curve of the peak of the UV signal at 210 nm compared to established NMP 
standards with a limit of quantification of 0.0625 mM NMP. There were at least three 
samples per group.  
 
2.2 Degradation 
 The degradation study was performed similarly to the release study except that 
implants were removed at specified time points, blotted to remove excess buffer, and 
frozen at -80°C until analysis. Initial polymer molecular weights and polymer degradation 
samples were analyzed with gel permeation chromatography with refractive index 
detection and polyethylene glycol standards for molecular weight calibration. Samples 
and standards were dissolved in dimethylformamide with 0.01 M LiBr and run at 45°C on 
a Viscotek GPCmax instrument with OmniSEC software (Version 4.6.0) (Malvern 
Instruments Ltd, England, Enigma Business Park, Grovewood Road, Malvern, 
Worcestershire, UK).  
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2.3 BMP-2 in Vitro Studies 
Bone morphogenetic protein-2 produced in E. coli in our laboratory (detailed 
expression and purification procedures can be found in prior literature [22]) was used for 
initial studies analyzing activity in different conditions and for release experiments. To 
test the activity of rhBMP-2 in various processing conditions, rhBMP-2 dissolved in 
acetic acid was lyophilized and resuspended in either acetic acid or NMP. Subsequently, 
it was further diluted in acetic acid, NMP, or combinations of the two. The activity of 
rhBMP-2 was measured by incubating samples with C2C12 cells and measuring alkaline 
phosphatase as early marker for bone formation. C2C12 cells (American Type Culture 
Collection, Manassas, VA) were cultured with DMEM (Life Technologies, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Life Technologies), 1% 200 mM L-
glutamine (Life Technologies) and 1% penicillin-streptomycin (10000 units/mL pen, 
10000 µg/mL strep, Life Technologies).  Cells were maintained at 37°C in a humidified 
chamber with 5% CO2. After 5-7 days incubation time, media was removed; cells were 
washed in Dulbecco’s PBS (Life Technologies), and incubated at room temperature for 
30 minutes with 0.56 M 2-amino-2-methyl-1-propanol (Sigma-Aldrich). Subsequently, 
cells were scraped from the plate and homogenized for 10 s. The cell lysate supernatant 
was combined with an equal volume of 0.56 M 2-amino-2-methyl-1-propanol (Sigma-
Aldrich) with 4mM MgCl2 and 20 mM disodium p-nitrophenyl phosphate (Sigma-Aldrich). 
Samples were heated at 37 °C for 10 min, NaOH was added to quench the reaction, and 
the optical density was read at 410 nm to measure alkaline phosphatase activity. 
After initial testing of different conditions, the rhBMP-2 dissolved at 1 mg/mL in 1 
mM HCl was added to the polymer and NMP by shaking at 37°C for 4-6 h for the release 
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studies. As in the NMP release studies, polymers were 40 wt% in NMP plus BMP 
solution.  The dissolved polymer with 10 µg rhBMP-2 was injected into a metal mesh 
basket and placed in 2 mL PBS with 6 M urea and maintained at 37°C on a turning-
wheel at 100 rpm.  Additionally, rhBMP-2 at the same concentration in the PBS/urea 
buffer were used as controls. Individual samples and controls were removed at each 
timepoint (7, 14, 21, and 28 days) and the supernatant was decanted and frozen at  -
20°C until analysis.  
A Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA) containing 48 
slots with a nitrocellulose membrane was used to measure the concentration of released 
rhBMP-2 as described earlier [23]. 200 µL of standards and appropriately diluted 
samples were added to the wells. The membrane was blocked for 1 h with NET-gelatin, 
incubated for 1 h with an anti-BMP-2/4 primary antibody (R&D Systems, Minneapolis, 
MN) diluted 1:500 and for 1 h with a polyclonal rabbit anti-goat IgG/HRP secondary 
antibody (Dako, Glostrup, Denmark) diluted 1:2000. After Electrochemiluminescence 
detection procedures, the film was scanned and analyzed with ImageJ (Version 1.47h, 
Wayne Rasband (NIH), rsb.info.nih.gov/ij/) to compare intensities of the test and control 
samples and standards. Samples are normalized to the rhBMP-2 controls to account for 
growth factor degradation. 
 
2.4 Rabbit Implantation Studies 
24 adult (12 month old) New Zealand white rabbits weighing between 3.5 and 4.2 
kg were used in this study with six rabbits per group. A 15 mm circular full-thickness 
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defect was created in the center of the calvaria using an electric burr. The bone was 
carefully removed, ensuring not to disturb the dura. A stepped titanium scaffold with an 
upper diameter of 17 mm, a lower diameter of 15 mm, and a total height of 3.8 mm was 
placed in the defect site. The titanium scaffold was produced by additive manufacturing 
using selective laser melting as described previously [24]. Rod thickness was 0.2 mm. 
After fabrication, all samples were ultrasonically cleaned in a 4% Deconex© 15PF 
(Beiersdorf, Münchenstein, Switzerland ) solution at 90°C for 5 min, then cleaned thrice 
in ultrapure water (resistivity 18.2MΩcm) for 15 min in an ultrasonic bath, and twice 
passivated in concentrated nitric acid (65% HNO3; Fluka) under ultrasonic agitation. The 
implants were processed in high purity oxygen RF plasma (PDC-32G; Harrick, oxygen 
purity 99.9995%, Carbagas) at 29.7W for 5 min in order to clean and sterilize the 
surface. Before the in vivo tests, the samples were packed and gamma sterilized with 25 
kGy. Rabbits were sacrificed after 16 weeks and the calvaria were removed for 
histological processing as described [24]. Four different conditions were tested: titanium 
scaffold alone, titanium scaffold with RG502, titanium scaffold with RG502 containing 12 
µg rhBMP-2 and titanium scaffold with RG752 containing 12 µg rhBMP-2. For the 
groups containing polymer, 200 µL of 40 wt% RG502 or RG752 dissolved in NMP with 
or without BMP-2 was deposited onto the center of the scaffold immediately before 
implanting.  
 
2.5 Histology 
The samples were first prepared with a sequential water substitution by ethanol 
process. Defatting took place in xylene. Next, the samples where infiltrated with methyl 
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methacrylate (MMA, Aldrich Chemistry, Japan) and embedded by adding to 100 mL 
MMA, 3 g of di-benzoylperoxid and 10 mL plastoid N (Merck AG, Zug, Switzerland). 
Polymerization was allowed to occur at 37°C in an incubator. Sections were prepared 
from the midst of the defects and ground to 25–50 µm. Thin-ground sections were 
stained with Coomassie brilliant blue and digital images taken to determine the bony 
regenerated area and the bony bridging via pixel measurement using ImageJ (Version 
1.47h, Wayne Rasband (NIH), rsb.info.nih.gov/ij/).  
Bony regenerated area is defined as the fraction of the titanium scaffold where 
bone formation has occurred. It includes bone, bone marrow and the scaffold embedded 
in bone. Bone bridging was determined in the middle section. First, the areas with bone 
tissue were projected onto the x-axis. Next, the stretches of the x-axis where bone 
formation had occurred at any level were summed up as described earlier [25, 26]. Bone 
bridging is given in percentage of the defect width (15 mm) where bone formation has 
occurred. 
 
2.6 Statistics 
The primary analysis unit was the animal. For all parameters tested, treatment 
modalities were compared with a Kruskal-Wallis Test, followed by Mann-Whitney signed 
rank test for independent data (IBM SPSS v.19). Significance was set at P < 0.05. Data 
from six rabbits per group are presented. Values are reported as mean ± standard 
deviation and displayed as box-plots ranging from the 25th (lower quartile) to the 75th 
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(upper quartile) percentile including the median and whiskers showing the minimum and 
maximum values. 
3. Results 
3.1 NMP Release 
Various polymers were tested to determine the effects of different factors on the 
release of NMP from the in situ forming implants. PLGA with different molecular weights 
but the same monomer ratio of 50% lactide and 50% glycolide were studied. The 
implants reproducibly filled the diameter of the mesh basket with a similar globular 
shape and a maximum 6% weight variation amongst implants. As shown in Figure 1a, 
higher polymer molecular weight led to faster release in the initial 24 h. RG502 released 
only 14.5% in the first 24 h, a low burst amount, whereas RG503 lost significantly more 
NMP, over 50% during this time period. However, the release rate of RG503 decreased 
after the initial 24 h and RG502’s rate increased after a brief stagnation, causing the 
release from RG502 to surpass that of RG503 after 10 days (Figure 1b).  
 
Figure 1: NMP release dependence on molecular weight. Weight average of RG502 is 14.5 kDa and 
of RG503 42.6 kDa. Cumulative NMP release of ISFI with 40% PLGA and 50 mol% lactide. Release 
over (a) 24 h (b) and 28 d. Mean ± SD (n=3). 
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The crossover point occurred at approximately day 7. At days 7 and 10, the 
release from the two polymers was not statistically different. By day 14, the RG502 had 
released 100% of the NMP, whereas RG503 released only about 75%. RG503 then 
released all of the NMP by day 21.   
In addition to comparing molecular weight, the ratio of the lactide and glycolide 
monomers was examined for its impact on NMP release. Figure 2a demonstrates the 
impact of varying the lactide percentage using polymers with the lowest molecular 
weight, with lower lactide percentages leading to less NMP release in the first 24 h. For 
example, R202, with 100 mol% PLA, released over twice as much of its NMP (40.6%) 
versus RG502 with 50 mol% lactide (14.5%). Over the course of four weeks, the results 
were reversed with the highest lactide content retaining NMP for the longest period of 
time, as seen in Figure 2b. RG502 (50 mol% lactide) reached 100% by day 7, and 
RG752 (75 mol% lactide) had a greater release than R202 (PLA) by day 14. After 28 
days, R202 (100% PLA) had only released 75% of the NMP, whereas 50 and 75 mol%-
lactide polymers freed all of the NMP earlier, at 14 and 21 days, respectively.  
Figure 2: NMP release dependence on lactide percentage. Lactide content for RG502 amounts to 
50 mol%, of RG752 to 75 mol% and of R202 to 100 mol%. Cumulative NMP release of ISFI with 40% 
PLGA and the lowest molecular weight. Release over (a) 24 h (b) and 28 d. Mean ± SD (n=3). 
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3.2 ISFI Degradation 
 
The degradation profiles of the ISFIs with the two polymers containing 50% 
lactide, RG502 (14.5 kDa) and RG503 (42.6 kDa), were evaluated. Using GPC analysis, 
the molecular weight distribution of the ISFI was measured at multiple time points from 1 
to 28 days. As shown in Figure 3, the average Mw of RG503 was initially much higher 
and the degradation rate steeper. However, by day 21, the RG503 ISFI Mw was no 
longer different from RG502.  
 
Figure 3: Degradation of ISFI prepared with RG502 or RG503 in PBS. Mean ± SD (n=3). 
3.3 BMP-2 Release 
In order to include rhBMP-2 in the ISFI system, studies were performed to 
determine the effects of the NMP ISFI system on the activity on BMP-2 and of the BMP-
2 on the NMP release. Since BMP-2 must be folded correctly to retain its activity and 
NMP could potentially disturb its secondary/tertiary structure, different process methods 
were evaluated. BMP-2 lyophilized and resuspended in 100% NMP resulted in a 
complete loss of activity, as measured by an alkaline phosphatase assay.  
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Furthermore, rhBMP-2 was no longer active when directly diluted in mixtures of 
NMP and acetic acid, even in 10% acetic acid/90% NMP (w/w), as seen in Figure 4. The 
fact that the polymers used in the ISFI system are not water soluble in higher than 10% 
aqueous solutions, limited the water content in the ISFI. Although rhBMP-2 directly 
dissolved in acetic acid/NMP mixtures inactivated the growth factor, rhBMP-2 dissolved 
in an aqueous acetic acid solution and then further diluted in NMP was active. Due to 
system constraints, the maximum percentage of NMP that could be tested was 97.5%, 
but the rhBMP-2 activity in this condition was equivalent to the controls of rhBMP-2 and 
NMP separately added to cells in the alkaline phosphatase assay. Therefore, particular 
processing methods maintained the activity of BMP-2 in a highly organic solvent 
environment.  
 
Figure 4: Activity of BMP-2 with NMP. Alkaline phosphatase activity was measured with lyophilized 
BMP-2 directly diluted in various percentage (w/w) NMP solutions with acetic acid (black bars) or 
BMP-2 first dissolved in an aqueous acetic acid solution and then diluted in various percentage 
NMP solutions (gray diagonal hashed bars). Cells only and NMP served as negative controls and 
BMP-2 (in aqueous solution) and BMP-2 (in aqueous solution) and NMP added directly to the well 
served as positive controls (solid gray bars). All data is normalized to the positive control of BMP-
2 (in aqueous solution). Mean ± SD (n=3). 
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Since the rhBMP-2 must be partially dissolved in aqueous solution to remain 
active, the effect of aqueous solution included in the IFSI system on the NMP release 
was tested using RG502, the lowest molecular weight polymer with 50 mol% lactide. 
During the first 24 h, the NMP release was slightly lower when water was included, 
although this difference was not significant (Figure 5). Over the course of 28 days, the 
cumulative NMP release was entirely equivalent for solvent with only NMP or with up to 
10% (w/w) water. It is important to note that the concentration of NMP was different 
since the total amount of NMP was higher when only NMP was used as the solvent. 
Thus, the addition of a small amount of water did not affect the ISFI system release 
characteristics.  
Figure 5: NMP release dependence on percentage of water in the solvent. Cumulative NMP release 
of ISFI with 40% PLGA, 50 mol% lactide, and the lowest molecular weight (RG502). The solvent 
dissolving the polymers was entirely NMP (no water), contained 8.3 or 10% (w/w) water. No BMP-2 
is included in these formulations. Release over (a) 24 h (b) and 28 days. Mean ± SD (n=3).  
 
The preliminary studies showed that there was potential to include rhBMP-2 
without dramatically changing the ISFI system to enable delivery of an active growth 
factor. Therefore, rhBMP-2 was added to the polymer and NMP in an acid solution as 
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10% (w/w) of the total solvent. rhBMP-2 release, measured at weekly intervals up to 28 
days, indicated that there was a very low level of release initially for both RG502 (50 
mol% lactide) and RG752 (75 mol% lactide) (Figure 6). By 21 days, release dramatically 
increased, with practically all of the rhBMP from the RG502 ISFI ending up in the 
supernatant whereas about only half of the rhBMP in the RG752 IFSI was released. At 
28 days, both polymers had released essentially all of the rhBMP.  
 
Figure 6: BMP-2 release dependence on lactide percentage. BMP-2 was included in the ISFI 
solutions and released into a PBS-urea buffer. BMP-2 was measured with a Bio-Dot apparatus with 
a primary anti-BMP-2/4 antibody. All data are normalized to the control of rhBMP-2 in PBS-urea at 
the same timepoint. Mean ± SD (n=3). 
 
3.5 In Vivo Bone Formation with ISFI  
 The ISFI with 50% lactide (RG502) and 75% lactide (RG752) were tested in vivo 
in a cranial defect model in rabbits. Since the degradation characteristics of the 
materials would also influence the healing of the defect, a titanium based scaffold was 
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used (Fig. 7a) so that the ISFI could be placed in the center of the defect (Fig. 7b). By 
doing so, the presence of the ISFI would not directly interfere with bone regeneration 
occurring predominantly from the defect margins besides the exposure to NMP, rhBMP-
2 and possibly degradation products released from the ISFI. For all the animals, the 
healing over a 16 week time period was uneventful. The histological sections revealed 
that bone formation has occurred in this critical size defect model to a great extent (Fig. 
7e-g). Defect bridging between the four groups was not significantly different (Fig. 7h). 
Without ISFI, 78 ± 35% of the defect was bridged. With NMP loaded 50% lactide ISFI 
defect bridging occurred to 49 ± 18%. In the presence of the NMP/rhBMP loaded 75 
mol% lactide ISFI, defect bridging occurred to 70 ± 19% and with the NMP/rhBMP 
loaded 50 mol% lactide ISFI, the mean defect bridging amounted to 83 ± 20%.  
 Without ISFI, 28 ± 15% of the implant was bony regenerated. With NMP loaded 
50% lactide, ISFI bony regeneration occurred to 21 ± 9%. In the presence of the 
NMP/rhBMP-2 loaded 75 mol% lactide ISFI (RG752), bony regeneration occurred to 29 
± 8%, and with the NMP/rhBMP-2 loaded 50 mol% lactide ISFI (RG502), the mean bony 
regeneration percentage was 50 ± 12% (Fig. 7k). Bony regeneration with the 
NMP/rhBMP-2 loaded 50 mol% lactide ISFI (RG502) was significantly better than with 
NMP/rhBMP-2 loaded 75 mol% lactide ISFI (RG752) (P=0.016), than with NMP loaded 
50% lactide (P=0.003), and than without ISFI (P=0.041). Therefore, for this critical size 
defect treated with a titanium-based scaffold, the rhBMP-2/NMP release profile of the 50 
mol% lactide ISFI was significantly better suited to enhance bony regeneration than that 
of the 75 mol% lactide ISFI. 
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Figure 7: In vivo bone formation. Titanium based lattice scaffolds (17/15 mm) in diameter were 
manufactured by selective laser melting, filled with ISFI and implanted in the calvarial bone of 
rabbits. a) Design of the scaffold. b) Loading of the scaffold with ISFI. c) Defect before implant 
placement. d) Placement of scaffold into the bony defect. Histology of the middle section: e) 
control is scaffold only, f) scaffold with ISFI 50% mol% lactide without BMP, g) scaffold with ISFI 
75 mol% lactide with BMP, h) scaffold with ISFI 50 mol% lactide with BMP, scale in mm is provided 
in e; bone appears blue with Toluidine-blue staining, titanium black. i) Box–plot for defect bridging 
and k) bony regenerated area. * indicates P values<0.05. Exact P values are provided in the result 
section. Mean ± SD (n=6).     
 
4. Discussion 
Since our laboratory’s discovery of NMP’s enhancing effects on BMP-2 and bone 
regeneration, it has been a goal to deliver this molecule in a sustained manner to take 
full advantage of its benefits. However, since NMP has a very low molecular weight 
(99.1 g/mol) and is both water and organic-soluble, it is difficult to retain in a delivery 
system. If the release of NMP could be extended to at least a couple of weeks, the NMP 
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would be available in the time period when BMP is exerting its action for regenerating 
bone.    
Here we report that the ISFI system with polyesters was successfully engineered 
to deliver NMP for more than two weeks, depending on the particular polymer used. The 
total duration of 100% release of NMP varied based on both polymer molecular weight 
and the ratio of the monomers. Lower molecular weight and higher lactide percentage 
polymers retained NMP for an overall longer time. These data correspond to other work 
that indicates that the nature of release profiles in the later time points is due to polymer 
degradation [27]. The polyesters with higher amounts of lactide exhibit slower 
degradation rates due to the more hydrophobic characteristic of the lactide monomer 
with the extra methyl group that hinders water access [28]. Liu and Venkatraman 
confirmed this by demonstrating that a 75 mol% lactide PLGA ISFI degrades slower than 
a 50 mol% lactide polymer, and had NMP release profiles that generally agreed with 
those found here [27].  Solorio et al. confirm similar trends in molecular weight 
degradation for ISFI with different initial molecular weights [29]. 
In addition to extending the release of NMP to a sufficiently long time frame, ISFI 
formulations were found that also restricted burst to a low amount in the first 24 h by 
using low molecular weight and low lactide percentage polymers. The pattern of burst 
followed by slow release has been previously shown to be typical for ISFI systems with 
PLGA and NMP [30]. However, high burst levels of NMP could potentially lead to toxic 
elevated concentrations of NMP. The amount of NMP burst increased with higher 
molecular weight, which corresponds to other studies that show greater burst release of 
small molecule drugs with higher molecular weight polymers [31, 32]. Prior research has 
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indicated that ISFIs that undergo fast phase separation result in a more porous 
morphology that accelerates initial release [16, 30, 33, 34]. A major contributing factor to 
the rate of phase inversion is the hydrophobicity of the polymer with a lower water 
affinity leading to more rapid phase transitions. Higher molecular weight polymers have 
been demonstrated to have lower water solubility, indicating that they are more 
hydrophobic [31], which can explain the relationship between burst and molecular weight 
demonstrated here. The higher burst rate of polymers with higher lactide content, which 
agrees with literature [27], can also be attributed to hydrophobicity. Since lactide is more 
hydrophobic than glycolide [28], the higher amount of lactide will lead to polymers of 
lower hydrophilicity and a faster transition rate.  
In order to create a more robust bone regeneration system, exogenous rhBMP-2 
was integrated into the ISFI to supplement the natural BMP-2 to enable greater NMP 
enhancement of BMP-2’s osteogenic effects for improved bone regeneration. By 
introducing rhBMP-2 already dissolved in an aqueous solution into NMP, the rhBMP-2 
retained its activity. Analysis of the additional water in the system mandated by the 
inclusion of rhBMP-2 in an aqueous solution had no significant impact on the NMP 
release rates even though polymer solubility differences between water and the solvent 
are the fundamental principle of formation of ISFIs. Since PLGA remains soluble with 
only a small percentage of water (6-12% aqueous solution for similar polymers in NMP) 
[20], only low levels of water could be included.  
rhBMP-2 release from the ISFI was studied using the two most promising polymer 
candidates that combine a low burst with long term NMP release: the lowest molecular 
weight polymers with 50 and 75 mol% lactide (RG502 and RG752). rhBMP-2 release 
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followed trends of the NMP release, although lower relative levels of BMP-2 release are 
seen until day 21. Overall, the ISFI retained the rhBMP-2 for an extended period of time 
with only a small amount released in the first two weeks.  
Previous animal studies with ISFIs and rhBMP by others are limited to a pilot 
study in rats [19, 35], that indicated that the system is osteoinductive and healed 
periodontal defects better than a collagen delivery vehicle. An optimization in terms of 
NMP and rhBMP release for bone regeneration has not been performed so far. Here 
bone regeneration was analyzed by two ISFI systems containing the same amount of 
rhBMP-2 and NMP, however, releasing them with different kinetics. For the application 
of the ISFI we used  titanium scaffolds (Fig. 7a) that can be permanently implanted and 
have inherent osteoconductive properties, as demonstrated in a rabbit calvarial defect 
model [24]. However, the primary role of the scaffold in this study is to serve as a carrier. 
Since the ISFI was placed in the middle of the scaffold a physical interference with bone 
in-growth occurring from the defect margins was omitted (Fig. 7b).  
The results revealed that compared to the titanium scaffold without ISFI and the 
titanium scaffold with the ISFI system with 50% lactide without rhBMP, only the ISFI 
system with a 50% lactide containing polymer performed significantly better. The same 
amount of NMP and rhBMP-2 released with different kinetics from the 75 mol% lactide 
containing polymer had no positive effect on bone regeneration determined 112 days 
post-surgery. A possible direct effect of the slower degradation of the 75% lactide 
compared to the 50% lactide was minimized in our system, since the ISFIs were placed 
in the center of the titanium scaffold. From the literature it is known that 80% 
degradation of the 75 mol% lactide implant is reached at 48 days compared to 30 days 
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for the 50 mol% lactide system [27].  The healing model used here continued until day 
112 post surgery, leaving sufficient time for undisturbed healing to occur for both 
materials.  
NMP and BMP release profiles, not degradation, are suspected to be the major 
contributors to differences in bone regeneration between the RG502 and RG752 
experimental groups. NMP at concentrations between 1 and 5 mM enhances BMP 
activity two to eight times and is most efficient at low BMP concentrations [9]. RG502, 
the 50 mol% lactide ISFI, may provide more optimal NMP concentrations for the greatest 
BMP enhancement due to its almost linear NMP release from the beginning up to 100% 
release on day 14  (Figure 2).  During these 14 days, less than 20% of the BMP was 
released according to the in vitro experiment, but its activity might have been enhanced 
several fold by the released NMP. Subsequently, the remaining 80% of the BMP-2 was 
released between day 14 and 21 (Figure 6). Overall, one can speculate that in the ISFI 
group of 50 mol% lactide containing polymer, the defect was exposed to a more optimal 
BMP activity from the beginning by low amounts of rhBMP-2 enhanced by NMP and 
later by higher amounts of rhBMP-2 until day 21. In the 75 mol% lactide group, both 
NMP and BMP release were more sustained until day 28, making it less likely that NMP 
or BMP threshold levels were reached so that the overall BMP activity remained 
inadequate to significantly stimulate bone regeneration.  
5. Conclusion 
 Taken together, our present findings demonstrate the possibility to use in situ 
forming implants for the dual delivery of rhBMP-2 and its enhancer NMP. For the 
rhBMP-2 to remain active, the growth factor has to be directly dissolved in aqueous 
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solution to replace up to 10% of the NMP content. Dependent on the polymer molecular 
weight and percentage of lactide of the ISFI system, release kinetics for NMP and 
rhBMP-2 can be tuned and sustained release over 28 days can be achieved. For bone 
regeneration purposes in a critical size defect in the calvarial bone of rabbits, the faster 
degrading and faster NMP and rhBMP-2 releasing system with 50 mol% lactide 
performed better in terms of bone bridging and significantly better for the amount of the 
bony regenerated area in the defect. Since the optimal release kinetics of NMP and 
rhBMP-2 might vary between applications, the ISFI systems have to be matched to the 
specific requirements.  
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Figure legends: 
Figure 1: NMP release dependence on molecular weight. Weight average of RG502 is 
14.5 kDa and of RG503 42.6 kDa. Cumulative NMP release of ISFI with 40% PLGA and 
50 mol% lactide. Release over (a) 24 h (b) and 28 d. Mean ± SD (n=3). 
Figure 2: NMP release dependence on lactide percentage. Lactide content for RG502 
amounts to 50 mol%, of RG752 to 75 mol% and of R202 to 100 mol%. Cumulative NMP 
release of ISFI with 40% PLGA and the lowest molecular weight. Release over (a) 24 h 
(b) and 28 d. Mean ± SD (n=3). 
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Figure 3: Degradation of ISFI prepared with RG502 or RG503 in PBS. Mean ± SD (n=3). 
Figure 4: Activity of BMP-2 with NMP. Alkaline phosphatase activity was measured with 
lyophilized BMP-2 directly diluted in various percentage (w/w) NMP solutions with acetic 
acid (black bars) or BMP-2 first dissolved in an aqueous acetic acid solution and then 
diluted in various percentage NMP solutions (gray diagonal hashed bars). Cells only and 
NMP served as negative controls and BMP-2 (in aqueous solution) and BMP-2 (in 
aqueous solution) and NMP added directly to the well served as positive controls (solid 
gray bars). All data is normalized to the positive control of BMP-2 (in aqueous solution).  
Mean ± SD (n=3). 
Figure 5: NMP release dependence on percentage of water in the solvent. Cumulative 
NMP release of ISFI with 40% PLGA, 50 mol% lactide, and the lowest molecular weight 
(RG502). The solvent dissolving the polymers was entirely NMP (no water), contained 
8.3 or 10% (w/w) water. No BMP-2 is included in these formulations. Release over (a) 
24 h (b) and 28 days. Mean ± SD (n=3). 
Figure 6: BMP-2 release dependence on lactide percentage. BMP-2 was included in the 
ISFI solutions and released into a PBS-urea buffer. BMP-2 was measured with a Bio-Dot 
apparatus with a primary anti-BMP-2/4 antibody. All data are normalized to the control of 
rhBMP-2 in PBS-urea at the same timepoint. Mean ± SD (n=3). 
Figure 7: In vivo bone formation. Titanium based lattice scaffolds (17/15 mm) in diameter 
were manufactured by selective laser melting, filled with ISFI and implanted in the 
calvarial bone of rabbits. a) Design of the scaffold. b) Loading of the scaffold with ISFI. 
c) Defect before implant placement. d) Placement of scaffold into the bony defect. 
Histology of the middle section: e) control is scaffold only, f) scaffold with ISFI 50% 
mol% lactide without BMP, g) scaffold with ISFI 75 mol% lactide with BMP, h) scaffold 
with ISFI 50 mol% lactide with BMP, scale in mm is provided in e; bone appears blue 
with Toluidine-blue staining, titanium black. i) Box–plot for defect bridging and k) bony 
regenerated area. * indicates P values<0.05. Exact P values are provided in the result 
section. Mean ± SD (n=6).     
 
